Proline‑mediated Dichloromethyl Tagging Enables Ultra‑pure Drug Synthesis
A new method uses the amino acid proline to precisely attach dichloromethyl groups to complex molecules, enabling ultra-pure drug synthesis with built-in quality control and expanding possibilities for advanced medicine design. drugdiscovery
Serum Proteomics Distinguishes Endurance versus Strength Adaptations
Adaptations to endurance vs strength training in elite athletes revealed by serum proteomics https://t.co/ii3xAiNEcT https://t.co/hBfQ0E0v9W
Why Anthropic Chose Coefficient Bio Over Bigger Rivals?
Reading up on the Coefficient Bio deal. I totally get the industrial logic around why Anthropic should care about drug discovery. But why this particular company? There's lots of more scaled players doing this. Can anyone educate me? https://t.co/akFVmRUaYw
DeepSeqAI Trains on Function to Future‑proof Biologics
Most AI protein tools are trained on structure. DeepSeqAI trains on function. They're running billions of experimental protein-protein interactions through their platform to map biologics against viruses, immune receptors, and the entire human proteome. The goal: candidates that hold up against...
CRISPR Turns 25: Explore Its Past, Present, Future
Introducing the GEN Keynote Webinar: "CRISPR at 25: The Past, Present, and Future of Genome Editing" Guest speaker: Rodolphe Barrangou @CRISPRchef May 4, 2026: noon ET/9 am PT Sponsored by @elevatebio https://t.co/cYsSsaod4Y via @GENbio
Busy Biotech Day Highlights Promising Advances and Insightful Commentary
As usual, excellent summary by @ldtimmerman @timmermanreport of busy and promising biotech news day - as always delivered w insight and heart (especially thoughtful comments re: revmed drug in context of poignant recent @BenSasse interview)
FDA Zeroes in on Houman Hemmati for CBER Lead
FDA narrows in on search for new biologics and vaccines leader - and we’re hearing @houmanhemmati is a top contender for CBER - https://t.co/qMx8wv32fG
Robust Bio Tools Demand Exhaustive Edge‑Case Testing
Hardest part of making bio tools is the endless testing of edge cases, to make sure that sequences are holy, circular permutation is accounted for, degenerate bases are considered, etc. To make robust code worthy of wetlab requires attention. I'm...
Off‑the‑Shelf CAR‑T Shows Promise Delaying Lymphoma Relapse
Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma https://t.co/UrSNYpQFqB by @gwendolynawu $ALLO + 25%
Pancreatic Cancer Drug Nearly Doubles Survival in Trial
Revolution pancreatic cancer drug nearly doubles survival in key trial https://t.co/SvJicU0LIz @ByJonGardner $RVMD + 38%
Revolution Medicines' Pancreatic Cancer Drug Shows Late‑Stage Success
This is big. All cancers suck. Pancreatic somehow manages to suck even more. Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial https://t.co/rFVsvi0mQD
Comprehensive Genomic Landscape of Small Bowel Adenocarcinoma Revealed
Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases [May 14, 2024] Aparicio et al. @BrJCancer https://t.co/xfznlhD4fh #sbcsm #cagenome HT @OncoThor
Multiplexed In‑Vivo Screening Drives Next‑Gen Drug Development
Multiplexed in vivo screening is the future of drug development. @ManifoldBio is multiplexing protein therapies in vivo. @GordianBio is multiplexing gene therapies in vivo. @waypointbio is multiplexing cell therapies in vivo. GT Bio is multiplexing LNPs in vivo. 50Y portcos all https://t.co/DT2AwXbKtB
ALLO May
Has $ALLO found a niche for allo Car-T at last? It's early days, so the answer is maybe. Via @APEXONCO -> https://t.co/bO3A1hpAY8
Rigorous Trials, Not Hype, Prove Cancer Drug Value
Today's $RVMD study outcome in pancreatic cancer is a good lesson for all the $IBRX @DrPatrick fans. Stop with all the hand-waving "cancer cure" podcasting social media nonsense. Shut up and run well-designed clinical trials with definitive endpoints. If you have...
Nanodiscs Reveal Antibody Interactions for HIV, Ebola Vaccines
Nanodisc technology enables viral surface proteins from HIV and Ebola to be studied within lifelike membrane environments, offering new insights into antibody interactions and accelerating the development of next-generation vaccines. vaccinedesign
Peptides Are Potent Therapeutics, yet only a Few Qualify.
“The big picture is that peptides are a legitimate, powerful class of therapeutics, but the legitimacy is confined to a relatively narrow subset of them.” —Peter Attia 👨🏻⚕️
Integrate scRNA‑seq PBMCs only After Evaluating Batch Effects
🧵 Should you integrate single-cell RNA-seq datasets or not? You've got PBMCs from multiple donors. Merge them—or keep them separate? Let's break it down.
Pancreatic Cancer Trials Yield Only 1‑2 Month Gains
I remember years ago in pancreatic cancer trials you were realistically looking for 1 to 2 months improvement in survival (at best) in pancreatic cancer trials. Bravo $RVMD.👏
Second‑line RVMD Improves Pancreatic Cancer Survival over First
As noted by others, the $RVMD dara mOS in 2nd line PDAC is better than mOS for current first-line regimens.
Low‑Cost Vaccine Creator Outshines Rogan’s Diet Critique
I make low cost vaccines for global health, including a Covid vaccine technology for $2-3 per dose reached 100 million people, bypassed big pharma, didn’t make money, and all these Rogan types can talk about is a joke I made...
One Gene Therapy Platform Could Cure Obesity and More
Eric Kelsic makes the compelling case on using gene therapy technology to eventually treat common diseases, like obesity: “Fundamentally, we all share the same genetics." Because our bodies run on the same genetic blueprint, a disease - whether common or rare -...
Daraxonrasib Halves Pancreatic Cancer Mortality, Doubles Survival
Finally, best news of the morning (and something you didn't expect so soon)... Revolution Medicines $RVMD daraxonrasib Ph3 results in second-line pancreatic cancer. Median overall survival in ITT patients (KRAS mutants + wild type combined) Dara 13.2 months vs chemo 6.7...
Allogeneic CAR‑T Achieves 42% MRD Boost, Safe Profile
Allogene $ALLO cema-cel interim ALPHA3 results just reported: B-cell lymphoma MRD negativity: cema-cel 58% vs observation 16% A 42% absolute difference in MRD clearance is better than expected. Clean safety profile, too. Allogeneic CAR-T may have found its role. Nice...
NVS Sells Darovasertib for $6M in Cash, Stock
Let's remember again that $NVS dumped off darovasertib for $2.5m in cash + $3.5m in $IDYA series B preferred stock.
Spyre's SPY001 Achieves 40% Remission in UC Trial
Spyre $SYRE just reported SPY001 (long-acting alpha4beta7 antibody) ulcerative colitis induction data. Here's the efficacy chart, notable for a 40% clinical remission rate at week 12, albeit with small number of patients. https://t.co/aEoLWPRjEL
LUT014 Shows Promise for RASi‑Induced Skin Rash
*Disclaimer : the company developing LUT014 is a Pontifax portfolio company.* Mechanistically LUT014 should be effective in RASi induced-rash as it was designed to activate RAS signaling in the skin so using it topically could de-couple RAS inhibition in the tumor...
High‑dose GLP‑1s Raise Optic Nerve Risk; Titrate Carefully
Patients are not asking if GLP-1s are right for them. They are asking how much you charge for tirzepatide. Shiv K. Goel breaks down what physicians need to know about oral Wegovy. Pharmacovigilance data: Wegovy carries nearly five times higher...
ALLO's Alpha-3 DLBCL Data Set to Spark Pre‑Market Move
Key $ALLO catalyst coming pre market today, with first data from cema-cel's Alpha-3 study in DLBCL consolidation. What to look for: https://t.co/a19BVEppqP
Darovasertib Shows Promise in Optimum-02 Uveal Melanoma Trial
$IDYA darovasertib data from registrational Optimum-02 trial in uveal melanoma are out. What to look for: https://t.co/1LQa0X6xJa
Repairing Aging Blood‑Brain Barrier to Halt CNS Disease
Aging of the Blood-Brain Barrier and Altered Permeability to Peripheral Immune Cells: Implications for Central Nervous System Disorders "We discuss interventions focused on barrier repair and immune recalibration, including the reinforcement of tight junctions, restoration of pericyte homeostasis, and modulation of...
Discrepancy in Mouse Counts Raises Partial Reprogramming Concerns
okay, tell me why you think browder et al had 21 mice in -dox and only 15 mice in the +dox group when they did partial reprogramming? https://t.co/gedJiKSRKo 6 more mice in the dox group got tummy aches and asked out of...
Rapid Lab Automation Needed to Scale Bio Testing
Interesting take on lab automation and serial scale vs parallel scale for data generation. Innovation in how we can rapidly Test more and more in the lab is badly needed as Design, Build and Learn capabilities in bio have exploded...
OSK Reprogramming Triggers Tumors, Undermining Mouse Study Confidence
OSK reprogramming also produces tumors see https://t.co/dNhcHVSBf3 cancer is a selective process clones grow out because they have a proliferative advantage or apoptotic disadvantage when mouse papers say no cancer despite the fact that half of lab mice die from cancer, i don't feel...
AI Powers Cancer Cures While Robots Learn Chores
AI is designing molecules that boost chemotherapy effectiveness by 70%, and humanoid robots are learning tasks by watching gig workers record themselves doing chores... we're literally teaching machines to cure cancer AND do our laundry.
Targeted mRNA Nanoparticles Halt Lung Tumors and Cachexia
Follistatin mRNA delivered via targeted lipid nanoparticles enables a dual therapeutic effect by simultaneously suppressing lung tumor growth and preventing cancer-associated muscle wasting (cachexia). https://t.co/56fCFZU0vk
Try My Pre‑Alpha TUI Plasmid Editor via Pip
If any1 wants to try my very unpolished and unfinished TUI plasmid editor in its very pre-alpha form, I reserved a slot on the ol pip bandwagon. Just type in: pip install splicecraft and I recommend runnin this often to update: pip install...
Aging Opens Chromatin, Altering Cell Behavior
The researchers then looked into the changes in the old cells that might explain such pronounced differences in behavior compared with the young cells. Liao Says "It seems as though chromatin opens up with age, so to speak." https://t.co/1kdRDunTea
IPSC Therapies Succeed; In‑vivo Reprogramming Remains Hype
your regular reminder that Yamanaka factor-driven production of iPSCs is already producing real medicine (eg dopaminergic neural progenitor for Parkinson's, cardiomyocyte sheets for heart failure & more) iPSC tech is not done in vivo... ppl isolate the well behaved cells away...
Daily Evoked Gamma Therapy Shows Safety and Cognitive Benefit
Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer’s disease 👉 “Our results demonstrate that 1-h daily treatment with [CogTx-001] was safe and well-tolerated and demonstrated potential clinical benefits in mild to moderate AD.” 🔘 Participants underwent...
24/7 Green Lab Services Available for $49‑$150
Great list of services from @americanwetware to ultimately have available 24/7. We have most of the green ones already in place w/ protocols in Ginkgo Cloud Lab for $49-$150, still need to add solubility measurement but can do that...
AbbVie’s Mirvetuximab Shows
AbbVie combo mirvetuximab posts 62.7% ORR; median DOR 11.2m. Efficacy boosts pipeline vs rich valuation and R&D hit. Trading insight: buy on pullback ahead of catalysts. 📈 — Viktor Kopylov, PhD, CFA More insights: t.me/si14Kopylov
AI Automation Will Multiply Scientist Jobs, Overcoming Lab Barriers
Couldn’t agree more. AI + automation = way more scientist jobs. Whole industry is massively held back by the cost and barriers to lab work. It’s like computing in the 1950s right now - back when we...
A Decade of DNA Innovation Powers AI‑Biology Convergence
Ten years ago, Emily Leproust had an idea to rewrite how DNA gets made. Most people thought it wouldn't work. Today, Twist Bioscience is the infrastructure layer for biotech and pharma worldwide. At SynBioBeta 2026, she's on the main stage with John...
Rare Diseases Need Molecular Surgery, Not Drug Barriers
The turning point for rare diseases, which affect >300 million people around the world. A call to get rid of its many structural obstacles, to consider it as molecular surgery unlike drug treatments gift link: https://t.co/DQ0OZ9tXXc https://t.co/RELCwTr88i
New TUI Plasmid Viewer Adds Golden Braid Automation
Cranking out some heavy updates to my TUI plasmid viewer. Golden Braid part domesticator and MoClo assembly automation. All the tools I ever dreamed of are coming to fruition. Really thankful for Claude Code. Follow along here; rapidly changin development https://t.co/3mkWtVqa1T...
One Blood Test Detects Multiple Cancers and Diseases
Detecting multiple cancers and other diseases from a single blood sample https://t.co/6gjjYY50dm via @medical_xpress #cancer #research
Aging Shares Disease Hallmarks, May Be Treatable
Is aging a disease? These authors reflect: “Disease is commonly defined as an abnormality of bodily structure or function, distinct from direct physical injury (Bulterijs et al., 2015). Whether ageing itself constitutes a disease has long been debated in the fields of...
Therapeutic Phlebotomy Restores Bone Marrow, Reverses Aging
Periodic Therapeutic Phlebotomy Mitigates Systemic Aging Phenotypes by Promoting Bone Marrow Function “our work provides preliminary evidence suggesting that periodic therapeutic phlebotomy exerts anti-aging effects by restoring bone marrow function and mitigating aging phenotypes, subsequently driving peripheral blood functional restoration.” 👉 “...
Safe Cell Reprogramming Restores Identity, Nature Reports
You're confused. Let me explain: My student @Y_Ryan_Lu worked for years to find a SAFE way to reprogram cells so they'd only RE-GAIN identity, not LOSE it, as Prof Yamanaka showed We tried innumerable combos to find the solution Story is @Nature...